About Diagnostear
Diagnostear is a company based in Tel Aviv (Israel) founded in 2013. Diagnostear has raised $2.85 million across 2 funding rounds from investors including Elcam Medical. Diagnostear offers products and services including TeaRx Dry Eye, TeaRx Red Eye, and TeaRx Tear Collector. Diagnostear operates in a competitive market with competitors including Pr3vent, Toku Eyes, TearLab, Gobiquity and Quantel Medical, among others.
- Headquarter Tel Aviv, Israel
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Diagnostear Technologies, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.85 M (USD)
in 2 rounds
-
Latest Funding Round
$2.85 M (USD), Series A
Oct 19, 2020
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Diagnostear
Diagnostear is a publicly listed company on the CSE with ticker symbol DTR in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Diagnostear
Diagnostear offers a comprehensive portfolio of products and services, including TeaRx Dry Eye, TeaRx Red Eye, and TeaRx Tear Collector.
Test for identifying and monitoring Dry Eye Syndrome.
Assesses conditions like adenoviral conjunctivitis and allergic conjunctivitis.
Microfluidic device for collecting tear fluid samples.
Funding Insights of Diagnostear
Diagnostear has successfully raised a total of $2.85M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $2.85 million completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Diagnostear
Diagnostear has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Elcam Medical.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked |
Investor details for Diagnostear
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Diagnostear
Investment portfolio details for Diagnostear
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Diagnostear
Detailed financials for Diagnostear
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Diagnostear Comparisons
Peer comparison for Diagnostear
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Diagnostear
Diagnostear operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Pr3vent, Toku Eyes, TearLab, Gobiquity and Quantel Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-based platform for newborn ophthalmic condition screening is offered.
|
|
| Locked | Locked | Locked |
AI-powered retinal images are analyzed for early disease detection.
|
|
| Locked | Locked | Locked |
Developer of diagnostic tests for detecting hyperosmolarity
|
|
| Locked | Locked | Locked |
Smartphone apps are developed to detect and track eye diseases.
|
|
| Locked | Locked | Locked |
Ultrasound and laser devices for ophthalmology are manufactured and marketed.
|
|
| Locked | Locked | Locked |
Provider of diagnostic, screening, and lens finishing equipment for eye care
|
Detailed competitors of Diagnostear
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Diagnostear
Complete news archive for Diagnostear
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Diagnostear
Diagnostear was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Diagnostear is headquartered in Tel Aviv, Israel.
Diagnostear is a funded company, having raised a total of $2.85M across 2 funding rounds to date.
Diagnostear is focussed on developing a point of care diagnostic test for dry eye syndrome (DES). It has developed an assay test called TeaRx based on various reagents that create color reactions when comes in contact with tear film and then provides a multi-parameter semi-quantitative analysis to identify the underlying causes of DES. As of October 2016, the test is in clinical development has shown positive second clinical study results in January 2016. The company DiagnosTear is part of BioLights XLVision Sciences ophthalmology cluster.
Diagnostear offers TeaRx Dry Eye, TeaRx Red Eye, and TeaRx Tear Collector.
Yes, Diagnostear is publicly traded on CSE under the ticker symbol DTR.
Diagnostear has 1 investor. Key investors include Elcam Medical.
The ticker symbol of Diagnostear is DTR on CSE.